Larimar Therapeutics (LRMR) said Thursday it has begun dosing adolescents aged 12 to 17 in its pediatric pharmacokinetic, or PK, run-in study of nomlabofusp, a treatment for Friedreich's ataxia.
In the study, participants will receive weight-based doses matching the 50mg adult dose and are randomized 2:1 to receive either nomlabofusp or a placebo daily for seven days, the biotechnology company said. Adolescents who complete the PK run-in study will be eligible to join the ongoing open-label extension, or OLE study.
The OLE study assesses safety, tolerability, PK, and Tissue frataxin levels in buccal and skin cells, as well as exploratory pharmacodynamic markers and clinical outcomes during long-term subcutaneous administration of nomlabofusp.
Larimar shares were up 1% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.